Close Menu
Home » Toronto Stock Exchange Reviewing GeneNews' Eligibility for Continued Listing

Toronto Stock Exchange Reviewing GeneNews' Eligibility for Continued Listing

Jan 19, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Canadian molecular diagnostics company GeneNews announced today that it has received notice that the Toronto Stock Exchange is reviewing its eligibility to remain listed on the TSX. GeneNews has 60 days to show that it is in compliance with the continued listing requirements of the exchange.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Whittling Down the Database

The New York City Police Department will be removing DNA profiles from a local database if they are from people who were never convicted of a crime, the New York Times reports.

Accusations and Certifications

Science reports that accusations of sexual assault against a microbiome researcher has also led to questions about his academic certifications.

DNA That Floats Behind

Wired reports that researchers are analyzing the DNA fish leave behind in water to study their populations.

Science Papers Include Thymus Cellular Map, Ancient Archaic Hominin Admixture

In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.

What's Popular?

In Business News

  1. Illumina Seeks Preliminary Injunction Against BGI in US Patent Infringement Case

  2. 10x Genomics Previews New Product Lineup Ahead of AGBT

    Premium

  3. New York Governor Plans Consortium for Alzheimer's Disease Genetic Research

  4. Genetron Health, InnoCare Partner on Cancer Clinical Trial Testing, CDx Development

  5. Invitae Q4 2019 Revenues Increase 47 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.